GH - Why Is Cancer Blood Test-Focused Guardant Health Stock Trading Lower Today? | Benzinga
Guardant Health Inc (NASDAQ: GH) shares are falling after the company announced it intends to appeal its verdict in the U.S. District Court for the District of Delaware related to patent right claims brought against Guardant by TwinStrand Biosciences Inc. and the University of Washington, regarding cancer-testing kits.
"We strongly disagree with this decision and will vigorously appeal for its overturn," said Helmy Eltoukhy, Guardant Health co-founder and co-CEO. "We believe the ruling ignores the strengths and merits of our R&D and intellectual ...